|

Alnuctamab Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: BMS-986349, CC-93269, EM901

Pipeline

Phase 1: 2

Top Sponsors

  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company1
  • Icahn School of Medicine at Mount Sinai1

Indications

  • Systemic Lupus Erythematosus1
  • Lupus1
  • Multiple Myeloma1
  • Cancer1

Birmingham, Alabama1 trial

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1

New York, New York1 trial

Alnuctamab for Refractory SLE (LATTE Study)

Icahn School of Medicine at Mount Sinai

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.